HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a report issued on Friday,Benzinga reports. The firm currently has a $21.00 target price on the stock.

A number of other research firms have also issued reports on PDSB. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. StockNews.com lowered shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $12.33.

PDS Biotechnology Stock Performance

Shares of PDSB traded down $0.24 during mid-day trading on Friday, hitting $2.01. 726,457 shares of the company’s stock were exchanged, compared to its average volume of 616,373. The business’s 50 day moving average is $3.21 and its two-hundred day moving average is $3.26. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $74.01 million, a P/E ratio of -1.65 and a beta of 1.93. PDS Biotechnology has a fifty-two week low of $1.53 and a fifty-two week high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. During the same quarter last year, the company posted ($0.37) earnings per share. On average, equities analysts expect that PDS Biotechnology will post -1.24 earnings per share for the current year.

Institutional Trading of PDS Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the company. Tempus Wealth Planning LLC acquired a new position in PDS Biotechnology during the 2nd quarter valued at $55,000. Ground Swell Capital LLC acquired a new stake in shares of PDS Biotechnology in the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in PDS Biotechnology during the second quarter worth about $115,000. Vontobel Holding Ltd. increased its holdings in PDS Biotechnology by 233.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock valued at $153,000 after purchasing an additional 28,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in PDS Biotechnology in the 2nd quarter valued at about $120,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.